Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

120
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
120
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

388
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
388
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

144
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
144
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

335
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
335

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions.

Journal of fungi (Basel, Switzerland)·2026
Same author

Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials.

Open forum infectious diseases·2026
Same author

The New Path Forward for Prior Authorizations: Navigating Differences in the Accepted Standards of Care, Society Guidelines, and FDA-approved Indications.

Open forum infectious diseases·2026
Same author

Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database.

Open forum infectious diseases·2025
Same author

Comparative Outcomes Following <i>Candida</i> Bloodstream Infection in Patients With Left Ventricular Assist Devices.

Open forum infectious diseases·2025
Same author

Geographic distribution and associated mortality of invasive aspergillosis and mucormycosis among Medicare enrollees in the United States (2008-2015).

The Journal of infection·2025
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
Same journal

Re-evaluating the 14-day rule: short-course antifungal therapy for uncomplicated candidaemia in a multicentre cohort study.

The Journal of antimicrobial chemotherapy·2026
Same journal

Impact of selective digestive decontamination on the pangenome composition of ESBL-E. coli.

The Journal of antimicrobial chemotherapy·2026
Same journal

Compounds of the γ-carboline family inhibit trans-translation.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.6K

Side effects associated with itraconazole therapy.

Matthew R Osborn1, Julio C Zuniga-Moya1, Patrick B Mazi1

  • 1Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, 4523 Clayton Ave, MSC 8051-0043-15, St. Louis, MO 63110, USA.

The Journal of Antimicrobial Chemotherapy
|December 10, 2024
PubMed
Summary
This summary is machine-generated.

Long-term itraconazole therapy for histoplasmosis caused side effects in about a quarter of patients. Higher itraconazole serum levels were linked to adverse events, suggesting monitoring may improve treatment outcomes.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K

Related Experiment Videos

Last Updated: Jun 5, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.6K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K

Area of Science:

  • Medical Mycology
  • Clinical Pharmacology

Background:

  • Itraconazole is a primary treatment for fungal infections like histoplasmosis.
  • Limited data exists on long-term itraconazole side effects compared to short-term use.
  • Fluconazole, often considered safer, shows significant toxicity in long-term treatment settings.

Purpose of the Study:

  • To assess the frequency, nature, and timing of itraconazole side effects in histoplasmosis patients.
  • To analyze treatment modifications due to side effects.
  • To investigate the relationship between patient characteristics, itraconazole serum levels, and side effect occurrence.

Main Methods:

  • A retrospective, single-center study of adult histoplasmosis patients on itraconazole for ≥28 days (2002-2021).
  • Characterization of reported side effects.
  • Propensity score matching to compare itraconazole serum levels in patients with and without side effects.

Main Results:

  • 27.8% of patients (63/227) experienced at least one side effect.
  • Common side effects included hepatotoxicity (7.0%), nausea/vomiting (6.6%), and diarrhea (6.2%).
  • Higher median itraconazole serum levels (2.9 vs. 1.8 mcg/mL) were observed in patients with side effects (P=0.009).

Conclusions:

  • Approximately 25% of patients on long-term itraconazole for histoplasmosis reported side effects.
  • Nearly two-thirds of affected patients required therapeutic intervention, including dose reduction or discontinuation.
  • Itraconazole demonstrated a lower side effect frequency compared to fluconazole in other studies.